Background/Objectives: In patients with malignancy, fluid electrolyte imbalance and renal dysfunction have been demonstrated to increase mortality and morbidity. The objective of this study was to evaluate body composition, and clinical and laboratory tests at baseline and at 3 months during chemotherapy and standard fluid therapy in patients with malignancy. Methods: This study included patients with an ECOG performance status of 0–1 who did not have clinically evident organ failure, brain tumors, or a need for intensive care treatment. All received standard fluid therapy and chemotherapy. Examinations, routine laboratory tests, and body composition measurements were performed at the beginning of chemotherapy and again after three months. Results: The number of hypervolemic patients increased. Although the body mass index (BMI) did not change compared to the baseline, serum levels of B-type natriuretic peptide (BNP), calcium, albumin, total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides increased at the second measurement. By month three, the frequency of overhydration (OH) increased. There was a significant, positive, moderate correlation between the difference in OH and the difference in BNP (p = 0.001). The leukocyte, neutrophil, neutrophil-to-lymphocyte ratio, and neutrophil-to-albumin ratio decreased (p < 0.05 for all). Body composition monitor (BCM) measurements revealed that the extracellular fluid/intracellular fluid ratio (E/I) increased at the second measurement (p = 0.001). Conclusions: The frequency of OH and BNP levels increased at three months. An initial fluid deficit or OH was associated with mortality. OH may mask sarcopenia in patients. Therefore, objective assessment of body composition is important for patient management to avoid OH and predict mortality. However, more studies with larger patient populations and long-term follow-up are needed.
Sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce cardiorenal events, but their association with insulin resistance in routine care is incompletely characterised, particularly where medication records cannot exclude exogenous insulin use. In this prospective, single-arm, single-centre cohort study, 54 adults with type 2 diabetes initiating an SGLT2 inhibitor were assessed at baseline, 3 and 6 months. Outcomes were HOMA-IR and the insulin-independent triglyceride–glucose (TyG) index within a family of 15 metabolic and laboratory variables, tested by Wilcoxon signed-rank test with Benjamini–Hochberg control and summarised as the rank-biserial correlation. Median HOMA-IR fell from 8.38 (IQR 3.47–13.26) to 3.14 (2.19–4.39), −62.6% (r = −0.79, adjusted p < 0.001), and the TyG index from 9.45 to 9.04 (−4.3%, r = −0.63, adjusted p < 0.001). Haemoglobin rose 5.0%, consistent with plasma-volume contraction. Change in HOMA-IR did not track change in HbA1c (ρ = −0.15, p = 0.27). An exploratory kidney-disease × time interaction was nominally significant for TyG (β = +0.31, p = 0.040) but not log-HOMA-IR (β = +0.39, p = 0.077). Because the design was single-arm and confounders unrecorded, these are associations observed during therapy, not treatment effects. The divergence between insulin-dependent and insulin-independent indices is relevant to endpoint selection in controlled studies.
OX40 (TNFRSF4) is a costimulatory T-cell receptor and OX40 agonists are in clinical development, yet its role in small cell lung cancer (SCLC) is still to be characterised. We analysed the discovery cohort (n = 77, 48 events), GSE60052 (n = 79 tumours; 48 with survival), GDSC1+GDSC2 (61 SCLC cell lines, 542 drugs) and human SCLC single-cell atlas (77,143 cells from primary and metastatic sites, 20 donors), using Cox models, FDR-controlled correlation, nested-model comparison and deconvolution. High TNFRSF4 showed a non-significant protective trend (pooled HR = 0.86 per SD, 0.68–1.10, p = 0.23); a nominal cutpoint did not survive correction for cutpoint search (p = 0.25). No drug reached FDR < 0.05 among 658 tests, including platinum agents and etoposide. TNFRSF4 tracked immune infiltration (13-gene score ρ = 0.76, p = 3 × 10−16) and was detected in 17.6% of T cells versus 1.03% of malignant cells in all 20 donors. OX40 was enriched in the POU2F3/SCLC-P subtype (p = 0.033), persisting after immune adjustment (β = 1.32, p = 0.011) but not replicating independently (p = 0.10). Adding TNFRSF4 to clinical-plus-immune models provided no meaningful discrimination gain (ΔC-index ≤ 0.005). Power was limited to HR ≥ 1.50 harmful or HR ≤ 0.67 protective, so the observed trend is undetectable at this size. Bulk OX40 therefore primarily reflects immune infiltration, and its SCLC-P association is a hypothesis for prospective testing.
Background/Objectives: Glucose-lowering treatment can change insulin resistance indices without demonstrating improved insulin sensitivity. We described these changes during sodium–glucose cotransporter-2 (SGLT2) inhibitor therapy in routine care. Methods: In this prospective, uncontrolled observational cohort, 54 adults with type 2 diabetes were assessed at baseline, 3 and 6 months. Background medication was abstracted from hospital and prescription records. Exploratory baseline-to-6-month comparisons used Wilcoxon signed-rank tests with Benjamini–Hochberg adjustment across 15 analysed outcomes. Results: Median HOMA-IR decreased from 8.38 (IQR 3.47–13.26) to 3.14 (2.19–4.39), a 62.6% reduction in group medians (rank-biserial r = −0.79; adjusted p < 0.001); in the 41 participants without documented insulin use, the reduction was 50.9% (r = −0.76). Median triglyceride–glucose (TyG) index decreased from 9.45 to 9.04 (−4.3%; r = −0.63; adjusted p < 0.001). Change in HOMA-IR was not significantly correlated with change in HbA1c (ρ = −0.15; p = 0.27). Conclusions: Both indices decreased during follow-up, including in participants without documented insulin use, but these observations cannot establish a treatment effect or improved insulin sensitivity. TyG requires no insulin measurement but remains sensitive to glucose- and triglyceride-lowering therapies, including SGLT2 inhibitors. Controlled studies with direct measures of insulin sensitivity are needed.